The UK Health Security Agency (UKHSA) has verified the presence of the BA.2.86 COVID-19 variant within the country, marking the first case. UKHSA reported this development on Friday, noting that the affected individual had no recent travel history, indicating potential community transmission in the UK.
The World Health Organization (WHO) and US health authorities, as of Thursday, are closely observing this new variant, BA.2.86. The variant’s implications remain uncertain.
The WHO has categorized BA.2.86 as a ‘variant under monitoring’ due to its numerous mutations. This variant has appeared in limited sequences across a handful of countries including Israel, Denmark, and the United States. In the UK, it is being monitored under the designation V-23AUG-01.
BA.2.86 stands out for its high mutation count and genomic distinctness from both its probable ancestor, BA.2, and presently circulating XBB-derived variants. Presently, there’s insufficient data to assess how its severity and immune response compare to other existing variants.
Dr. Meera Chand, Deputy Director of UKHSA, indicated that V-23AUG-01’s variant status stems from international transmission and significant genome mutation. UKHSA is closely evaluating the situation and intends to provide further details in the future.
While most virus changes, including SARS-CoV-2, have minimal effect on their properties, some changes can impact properties such as transmissibility, disease severity, vaccine efficacy, and public health measures.
Globally, as of August 16, 2023, there have been 769,774,646 confirmed cases of COVID-19 with 6,955,141 reported deaths to WHO. Vaccine administration has reached a total of 13,498,472,794 doses as of August 13, 2023.
